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Radiation-induced malignancies following radiotherapy for breast
cancer
R Roychoudhuri*,1, H Evans1, D Robinson1 and H Møller1
1Thames Cancer Registry, Division of Cancer Studies, Guy’s, King’s and St. Thomas’ School of Medicine, 1st Floor, Capital House, 42 Weston Street,
London SE1 3QD, UK
With advances in diagnosis and treatment, breast cancer is becoming an increasingly survivable disease resulting in a large population
of long-term survivors. Factors affecting the quality of life of such patients include the consequences of breast cancer treatment, which
may have involved radiotherapy. In this study, we compare the incidence of second primary cancers in women who received breast
radiotherapy with that in those who did not (non-radiotherapy). All women studied received surgery for their first breast cancer.
Second cancers of the lung, colon, oesophagus and thyroid gland, malignant melanomas, myeloid leukaemias and second primary
breast cancers were studied. Comparing radiotherapy and non-radiotherapy cohorts, elevated relative risks (RR) were observed for
lung cancer at 10–14 years and 15 or more (15þ ) years after initial breast cancer diagnosis (RR 1.62, 95% confidence interval [CI]
1.05–2.54 and RR 1.49, 95% CI 1.05–2.14, respectively), and for myeloid leukaemia at 1–5 years (RR 2.99, 95% CI 1.13–9.33), for
second breast cancer at 5–10 years (RR 1.34, 95% CI 1.10–1.63) and 15þ years (RR 1.26, 95% CI 1.00–1.59) and oesophageal
cancer at 15þ years (RR 2.19, 95% CI 1.10–4.62).
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With recent advances in diagnosis and treatment, breast cancer is
becoming an increasingly survivable disease resulting in a large
population of long-term survivors. Clearly, factors affecting the
quality of life and length of survival of such patients include the
consequences of breast cancer treatment, which may have involved
radiotherapy. There is copious evidence for the link between
radiation exposure and carcinogenesis, especially from the
epidemiological study of survivors of atomic bomb irradiation
(Land et al, 2003; Preston et al, 2003) and it has been suggested
that irradiation of surrounding tissues during breast radiotherapy
can, through similar mechanisms, cause second cancers to develop
within these tissues (Harvey and Brinton, 1985; Neugut et al, 1999).
While the benefits of radiotherapy outweigh the risks of
developing subsequent cancers, the presence of such risks could
implicate the need for further investigation into methods of
minimising the radiation dose delivered to surrounding tissues or
the volume of such tissues exposed.
Several different factors may contribute to the co-occurrence of
multiple primary cancers in an individual besides radiation-
induced oncogenesis: genetic predisposition, environmental ex-
posure to carcinogens, reproductive factors, misdiagnosis of
metastases as primary cancers, increased medical surveillance
following the first cancer and other treatment-related effects.
Temporal patterns underlying associations in the co-occurrence of
cancers are useful in discerning the predominant aetiology
underlying these associations. For example, genetic and environ-
mental predisposition would be expected to cause a general,
temporally nonspecific increase in the incidence of second cancers,
while iatrogenic tumours resulting from the side effects of
treatment for a first cancer would be expected to develop some
time after this treatment. Indeed, Boice et al (1996) have suggested
that cancers resulting from an exposure to radiation would develop
within predictable time windows: after 10 years for solid tumours
and within 5 years for leukaemias.
In this paper, we have used one of the world’s largest
population-based cancer registries to compare the incidence of
certain second cancers in patients who either have, or have not,
received radiotherapy alongside surgery for breast cancer. Cancers
of the lung, colon, oesophagus and thyroid gland, along with
malignant melanomas of the skin, myeloid leukaemias and second
primary breast cancers, were analysed, since these neoplasms have
been previously associated with radiotherapy of the breast (Harvey
and Brinton, 1985; Evans et al, 2001; Deutsch et al, 2003; Smith
et al, 2003).
MATERIALS AND METHODS
The Thames Cancer Registry (TCR) database was used to identify
breast cancer patients who either had or had not received
radiotherapy alongside surgery for breast cancer, and who went
on to develop further primary cancers. The Thames Cancer
Registry is a population-based registry which collects data on
cancer in residents of South East England (currently a population
of 14 million). Data collection began in 1960 in the South Thames
Region and was extended in 1985 to also cover the North Thames
Region. The patients registered at the TCR represent a cohort of
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individuals followed up from diagnosis to death, and the database
currently contains over 1.5 million incident cancers.
In the analysis of multiple cancers, it is important that
metastases or recurrences of the initial tumour should not be
misclassified as primary tumours. The rules for accepting a second
tumour as a new primary rather than a metastasis are well defined
and nationally agreed among the UK cancer registries. As a general
rule, a new primary tumour needs to be at a different anatomical
site and of a different histological type from the first tumour, or to
be stated explicitly as being a new tumour by the treating clinician.
Index cohorts were created by extracting all registrations of
females with a first breast cancer who received surgery for this
breast cancer, resident in the North or South Thames region and
diagnosed between 1 January 1961 and 31 December 2000 from the
TCR database. Those who also received radiotherapy for this
breast cancer were placed into the RT cohort, while those who did
not were placed into the non-RT cohort, and analyses were
performed separately on these subgroups. Women who received
additional treatment (e.g. chemotherapy) for their primary breast
cancer were excluded from the study. For women diagnosed with
two or more cancers subsequent to breast cancer, only the first
subsequent cancer was considered, since if multiple cancers were
considered treatments for these cancers themselves might cause
additional effects on the incidence of subsequent cancers.
Second cancers occurring within 1 year of the initial cancer, at
the same site, with the same laterality and histology were excluded,
as were patients with a missing date of birth and cancers without a
year of diagnosis or without information on the location of
residence of the patient at the time of diagnosis. Patients with two
cancers at different sites diagnosed on the same day were also
excluded from the analysis.
To obtain standardised incidence ratios of subsequent cancers
following diagnosis of breast cancer, we computed person-years at
risk in each cohort and applied appropriate population-based
cancer incidence rates. For a given subsequent cancer site, person-
years at risk were calculated from the date of diagnosis of breast
cancer to the date of first diagnosis of cancer at the specified site or
to the exit date (date of death, loss to follow up or 85th birthday,
whichever was earlier). Patients diagnosed prior to 1 January 1971
were followed up actively, obtaining death information, until 31
December 1982. These were censored at this date. Patients
diagnosed after 1 January 1971 were followed up through the
NHS Central Register, which provides notification of all deaths
routinely to the registry. Age- and period-specific cancer incidence
rates for the region covered by the TCR were then applied to the
cohort for intervals following breast cancer diagnosis of less than 1
year, 1– 4, 5–9, 10– 14 and 15 or more (15þ ) years to calculate the
number of subsequent tumours that would be expected for each
site in each specific interval. This number was compared with the
observed number to obtain a standardised incidence ratio (SIR)
estimate, and exact 95% confidence intervals were calculated
assuming an underlying Poisson distribution. Relative risks (RRs)
were calculated by comparison of the SIR in the RT and non-RT
cohorts, and exact 95% confidence intervals calculated using the
method described by Breslow and Day (1982). Calculations were
performed using the statistical package Stata (StataCorp, 1999).
The following cancer sites were studied, classified according to the
10th revision of the International Classification of Diseases (ICD)
(World Health Organisation, 1992): lung and bronchus (C34)
referred to in this paper as simply lung cancer, breast (C50), colon
(C18), oesophagus (C15), malignant melanoma of the skin (C43),
thyroid (C73) and myeloid leukaemia (C92).
RESULTS
A total of 64 782 women who had received surgery following a first
cancer of the breast were included in this study. Of these, 33 763
received radiotherapy in addition to surgery for this cancer (RT
cohort), and 31 019 did not (non-RT cohort). A total of 5217
second primary tumours were detected, and 2857 of these second
tumours were at one of the sites of interest.
Results are tabulated by interval of follow-up and second cancer
site in Table 1, and results for lung cancer, myeloid leukaemia,
breast cancer and oesophageal cancer are shown graphically in
Figure 1.
The RR of developing lung cancer was shown to be significantly
elevated in the RT cohort compared with the non-RT cohort at
both 10 –14 and 15 or more (15þ ) years after diagnosis of breast
cancer (RR 1.62, 95% CI 1.05– 2.54 and RR 1.49, 95% CI 1.05–2.14,
respectively). The SIRs for lung cancer in the 1–5-year period of
follow-up were low in both groups, and there was also found to be
a decreased RR of lung cancer within the first year following
diagnosis of breast cancer in the RT cohort when compared with
the non-RT cohort (RR 0.40, 95% CI 0.17– 0.85). A significantly
increased RR of developing myeloid leukaemia was observed at 1–
5 years (RR 2.99, 95% CI 1.13–9.33). There was an elevated SIR of
second primary breast cancer in both the non-RT and RT cohorts,
regardless of the period of follow-up. However, at 5 years of follow-
up and longer, the excess was greater in the RT cohort, particularly
so in the interval from 5 to 10 years (RR 1.34, 95% CI 1.10–1.63)
and 15þ years (RR 1.26, 95% CI 1.00–1.59). Considered over the
whole period of follow-up from 5 years and onwards, the SIRs were
1.21 and 1.40 in the RT cohort and non-RT cohort, respectively,
and the overall RR was 1.16 (95% CI 1.02–1.31).
The RR of oesophageal cancers was increased significantly 15þ
years after diagnosis and radiotherapy (RR 2.19, 95% CI 1.10–
4.62). There were no significant differences observed in the
incidence of second cancers of the colon, thyroid gland or
malignant melanomas of the skin in the RT cohort when compared
with the non-RT cohort in any period of follow-up.
DISCUSSION
In this study, we have used a large population-based cancer
registry to examine the effects of radiotherapy for breast cancer on
the incidence of subsequent second cancers. Such epidemiological
analyses, however, can be highly sensitive to biasing factors. By
selecting RT and non-RT cohorts, one also consistently selects for
those factors taken into account when a clinical decision is made
concerning whether or not to use radiotherapy. Genetic and
environmental predispositions may underlie the co-occurrence of
multiple cancers in an individual, and if these predispositions also
underlie other factors affecting the aforementioned clinical
decisions then bias may be introduced. Only patients who had
received surgery for breast cancer were included in this study
rather than all first tumours of the breast. This is likely to reduce
any bias between the RT and non-RT cohorts by reducing
variability in the parent population. The authors of two other
important epidemiological studies of a similar nature have also
usefully used surgery as the background for their RT and non-RT
cohorts (Boice et al, 1985; Brenner et al, 2000), as acknowledged by
Hall and Wuu (2003). Boice has suggested that a certain latency
period passes before tumours resulting from exposure to radiation
develop, and that this period depends upon the cancer type.
Leukaemias are expected to develop within 5 years, while an
induced excess of solid tumours is observed after 10 or more years
(Boice et al, 1996), and there is copious epidemiological evidence
to support this (Neugut et al, 1993; Rubino et al, 2003;
Zablotska and Neugut, 2003). Even if similar latencies exist for
exposure to other carcinogenic breast cancer treatments, a
significant excess in the incidence of cancers in the RT cohort
compared with the non-RT cohort and following the expected
latency period would support radiotherapy as the predominant
aetiology.
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A significant excess in the incidence of myeloid leukaemia 1–5
years after breast cancer diagnosis was observed in radiotherapy
patients. This is consistent with previous epidemiological studies
(Curtis et al, 1992; Smith et al, 2003). Smith et al, however, also
found an excess incidence of acute myeloid leukaemias and
myelodysplastic syndrome to be associated with therapy in those
patients who received doxorubicin combined with intensified
cyclophosphamide doses (requiring granulocyte colony-stimulat-
ing factor support) when compared with those who received
doxorubicin combined with cyclophosphamide therapy at the
standard dose. In our study, women who received chemotherapy
in addition to surgery were excluded.
An excess incidence of lung cancer was observed at 10 years or
more after radiotherapy. This is consistent with other studies
(Deutsch et al, 2003; Zablotska and Neugut, 2003). Smoking is the
main cause of lung cancer (Ernster, 1994). The SIRs for lung cancer
in both the RT and non-RT cohorts were found to be low,
especially at 1– 10 years after breast cancer diagnosis. It is possible
that the diagnosis of cancer in some of these individuals prompted
voluntary smoking cessation with a subsequent decrease in lung
cancer incidence, as has previously been observed following
smoking cessation (Peto et al, 2000). However, information on the
smoking status of patients in our study was not available.
It is also of note that, in radiotherapy patients, a significant
decrease in the observed incidence of lung cancer was found in the
year following diagnosis of breast cancer. This could be due to
genuine decreased incidence, underdiagnosis or chance. Under-
diagnosis could result from the misinterpretation of the signs and
Table 1 Standardised incidence ratios and RR of developing second cancer for women who received surgery and radiotherapy for breast cancer (RT),
compared with those who received surgery only (non-RT), tabulated by second cancer site and interval of follow-up
Nonradiotherapy cohort Radiotherapy cohort
Interval
(years)
Observed
no. of
tumours
Expected
no. of
tumours SIR 95% CI
Observed
no. of
tumours
Expected
no. of
tumours SIR 95% CI
Relative
Risk 95% CI
Lung
0– 27 22.8 1.18 0.78–1.72 10 21.1 0.47 0.23–0.87 0.40 0.17–0.85
1– 50 79.4 0.63 0.47–0.83 50 77.4 0.65 0.48–0.85 1.03 0.68–1.55
5– 60 77.5 0.77 0.59–1.00 69 81.6 0.85 0.66–1.07 1.09 0.76–1.57
10– 34 56.0 0.61 0.42–0.85 62 63.0 0.98 0.75–1.26 1.62 1.05–2.54
15+ 55 55.9 0.98 0.74–1.28 80 54.5 1.47 1.16–1.83 1.49 1.05–2.14
Myeloid Leukaemia
0– 2 2.0 1.02 0.11–3.67 2 1.8 1.13 0.13–4.08 1.11 0.08–15.3
1– 6 6.8 0.89 0.32–1.93 17 6.4 2.66 1.55–4.25 2.99 1.13–9.33
5– 7 6.5 1.08 0.43–2.23 8 6.7 1.19 0.51–2.35 1.10 0.35–3.59
10– 5 4.6 1.09 0.35–2.55 3 5.1 0.59 0.12–1.72 0.54 0.08–2.78
15+ 2 4.5 0.45 0.05–1.62 9 4.3 2.09 0.95–3.96 4.66 0.97–44.8
Breast
0– 99 56.6 1.75 1.42–2.13 78 58.7 1.33 1.05–1.66 0.76 0.56–1.03
1– 266 186.4 1.43 1.26–1.61 248 200.5 1.24 1.09–1.40 0.87 0.73–1.03
5– 173 167.5 1.03 0.88–1.20 264 190.7 1.38 1.22–1.56 1.34 1.10–1.63
10– 151 113.1 1.34 1.13–1.57 158 132.6 1.19 1.01–1.39 0.89 0.71–1.12
15+ 138 101.6 1.36 1.14–1.60 170 99.5 1.71 1.46–1.99 1.26 1.00–1.59
Oesophagus
0– 5 3.9 1.29 0.41–3.00 1 3.3 0.31 0.00–1.71 0.24 0.00–2.11
1– 11 13.5 0.81 0.41–1.46 13 12.1 1.07 0.57–1.83 1.32 0.55–3.25
5– 18 13.3 1.35 0.80–2.14 14 13.3 1.05 0.57–1.76 0.78 0.36–1.66
10– 11 9.8 1.12 0.56–2.01 11 10.9 1.01 0.50–1.81 0.90 0.35–2.29
15+ 13 10.2 1.28 0.68–2.18 28 10.0 2.80 1.86–4.05 2.19 1.10–4.62
Malignant melanoma of the skin
0– 4 2.7 1.51 0.41–3.86 5 3.3 1.51 0.49–3.51 1.00 0.22–5.15
1– 11 8.7 1.26 0.63–2.26 14 11.4 1.23 0.67–2.06 0.97 0.41–2.36
5– 6 7.9 0.76 0.28–1.66 8 11.0 0.73 0.31–1.44 0.96 0.29–3.35
10– 4 5.4 0.74 0.20–1.89 8 7.9 1.01 0.44–2.00 1.37 0.37–6.20
15+ 9 5.8 1.55 0.71–2.95 10 6.3 1.59 0.76–2.93 1.03 0.37–2.85
Colon
0– 22 18.1 1.22 0.76–1.84 11 15.0 0.73 0.37–1.31 0.60 0.26–1.30
1– 48 60.7 0.79 0.58–1.05 49 53.6 0.91 0.68–1.21 1.16 0.76–1.76
5– 42 55.2 0.76 0.55–1.03 55 54.1 1.02 0.77–1.32 1.34 0.88–2.05
10– 27 36.0 0.75 0.49–1.09 27 39.6 0.68 0.45–0.99 0.91 0.51–1.61
15+ 20 29.0 0.69 0.42–1.06 21 28.2 0.74 0.46–1.14 1.08 0.56–2.10
Thyroid
0– 2 4.6 0.44 0.05–1.58 5 4.7 1.06 0.34–2.48 2.43 0.40–25.7
5– 6 3.1 1.96 0.72–4.27 4 3.4 1.18 0.32–3.01 0.60 0.13–2.56
10– 1 2.0 0.49 0.01–2.74 3 2.3 1.28 0.26–3.75 2.60 0.21–137
15+ 2 1.8 1.09 0.12–3.92 5 1.8 2.78 0.90–6.48 2.56 0.41–26.3
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symptoms of lung cancer as side effects of recent breast
radiotherapy. If such is the case, then this certainly deems further
investigation. If a genuine decrease in incidence of lung cancer
results from radiotherapy, it is perhaps possible that small
incipient lung tumours responded to breast RT with a subsequent
decrease in incidence, though this is unlikely upon consideration
of the typical radiotherapy dose distribution.
There was a generally elevated incidence of breast cancer above
the standardised baseline in both the RT and non-RT cohorts,
consistent with a genetic or environmental predisposition
hypothesis. However, the isolated increase in RR in the RT cohort
at 5– 10 years is most plausibly attributed to a direct effect of RT.
In this 5 –10-year interval, the proportion of the second breast
cancers which were contralateral was the same in the two cohorts
(94%). Considering the type of surgery that was performed in this
group of patients, 20% of the second breast cancers in the non-RT
cohort occurred in women who had initially been treated with a
partial removal of the breast, as opposed to radical mastectomy. In
the RT cohort, the corresponding figure was significantly higher
(42%). This suggests that a larger proportion of women with a
radiation-induced second breast cancer had initially had lumpect-
omy rather than mastecotomy, when compared with the non-RT
cohort.
An excess of cancer of the colon following breast cancer
radiotherapy has been reported previously (Harvey and Brinton,
1985). However, no significant excess was observed in this study.
Similarly, no significant increase in incidence of thyroid cancers
was observed in any interval in radiotherapy recipients compared
with non-RT recipients, although this may have been due to
limited statistical power associated with the general low incidence
of this cancer. We found a significant increase in the incidence
of oesophageal cancers 15 or more years after radiotherapy.
There is increasing use of breast conservation therapy (lumpec-
tomy and radiotherapy) for Stage I and II invasive carcinoma
and for ductal carcinoma in situ, and evidence exists to support its
efficacy when compared with mastectomy alone (Jacobson et al,
1995). Deutsch has suggested that this trend, along with renewed
enthusiasm for postmastectomy chest wall and regional lymph
node irradiation, may lead to increasing numbers of women with
breast cancer being exposed to pulmonary irradiation, with
possible implications for second cancer incidence (Deutsch et al,
2003). However, a study by Zablotska and Neugut (2003) has
shown only post-mastectomy radiotherapy, and not post-lumpec-
tomy radiotherapy, to be associated with significantly increased
incidence of lung cancers after 10 years. It is uncertain what
effect new technologies such as intensity-modulated radiation
therapy will have on the incidence of second cancers compared
with conventional three-dimensional conformal radiation therapy,
although Hall and Wuu (2003) have pointed out that, since the
technique requires the use of more fields, a larger volume of
surrounding tissues are exposed to a lower dose than in
conventional radiotherapy, and since these fields are modulated
and therefore require a longer charging time for the energiser, the
patient is exposed to a higher level of radiation leakage. By
applying a calculated dose –response relationship to dose –volume
histograms of radiotherapy by conventional and intensity-modu-
lated methods, the authors have concluded that intensity-
modulated radiation therapy may result in a higher incidence of
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Figure 1 Standardised incidence ratios of lung cancer, myeloid leukaemia, breast cancer and oesophageal cancer in patients who received surgery and RT
for breast cancer, and in patients who received surgery only (non-RT), plotted against interval following breast cancer diagnosis. Vertical bars are 95%
confidence intervals.
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second primary cancers than conventional conformal radio-
therapy.
With a fairly low overall incidence of second cancers, the
excess risk associated with radiotherapy remains small. In
absolute terms, the number of observed excess second cancers
in the RT cohort of 33 763 women which can be attributed
to radiation exposure is about 160. It is therefore important to
note that in breast cancer the benefits of radiotherapy still
very much outweigh the risks of developing subsequent second
cancers.
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